Winrevair (sotatercept) meets primary endpoint in Phase 2 CADENCE study on patients with a subset of pulmonary hypertension due to left heart disease (PH-LHD), November 18, 2025
Combined post- and precapillary pulmonary hypertension (CpcPH) represents a subset of pulmonary hypertension due to left heart disease (PH-LHD), also known as World Health Organisation Group 2 pulmonary hypertension. There are currently no treatments specifically approved for this condition. The CADENCE met its primary endpoint, showing a statistically significant and clinically meaningful reduction in pulmonary […]

